KNSAKiniksa Pharmaceuticals International, plc
Is it safe?
Nothing alarming, nothing pristine: insiders quiet and big price swings.
Insiders were net sellers (-$668K, 90 days to Oct 8, 2026), selling is often routine.
Large price swings, high volatility. Worst drawdown -83% · now at/near its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can KNSA take a bad year?
The deepest fall in KNSA's price history on file is −83%; it is 1.3% below its high today.
Worst drawdown on file · −1.3% today
- Annualised volatility
- 49%
Annualised volatility · roughly twice as jumpy as the market
Details›
- Cash and short-term investments
- $468M
- EBITDA, trailing twelve months
- $94M
- Operating profit, trailing twelve months
- $93M
- Annualised volatilitytwo years of daily moves
- 49%
- Worst drawdown on file
- −83%
- Below its 52-week high
- 1.3%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers, Specialty & Generic
Ranks #28 of 41 by RyuScore